

Robert A Redd

List of Publications by Citations

Source: <https://exaly.com/author-pdf/3031813/robert-a-redd-publications-by-citations.pdf>

Version: 2024-04-28

This document has been generated based on the publications and citations recorded by exaly.com. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

77
papers

3,231
citations

25
h-index

56
g-index

87
ext. papers

4,525
ext. citations

6.5
avg, IF

4.66
L-index

#	Paper	IF	Citations
77	Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. <i>Nature Medicine</i> , 2018 , 24, 679-690	50.5	659
76	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Journal of Clinical Oncology</i> , 2016 , 34, 2690-7	2.2	472
75	Prognostic Mutations in Myelodysplastic Syndrome after Stem-Cell Transplantation. <i>New England Journal of Medicine</i> , 2017 , 376, 536-547	59.2	383
74	Major Histocompatibility Complex Class II and Programmed Death Ligand 1 Expression Predict Outcome After Programmed Death 1 Blockade in Classic Hodgkin Lymphoma. <i>Journal of Clinical Oncology</i> , 2018 , 36, 942-950	2.2	175
73	Topological analysis reveals a PD-L1-associated microenvironmental niche for Reed-Sternberg cells in Hodgkin lymphoma. <i>Blood</i> , 2017 , 130, 2420-2430	2.2	174
72	Classical Hodgkin Lymphoma with Reduced β 2M/MHC Class I Expression Is Associated with Inferior Outcome Independent of 9p24.1 Status. <i>Cancer Immunology Research</i> , 2016 , 4, 910-916	12.5	118
71	Pembrolizumab in Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2019 , 37, 3291-3299	2.2	116
70	Nivolumab for Newly Diagnosed Advanced-Stage Classic Hodgkin Lymphoma: Safety and Efficacy in the Phase II CheckMate 205 Study. <i>Journal of Clinical Oncology</i> , 2019 , 37, 1997-2007	2.2	110
69	Mass cytometry of Hodgkin lymphoma reveals a CD4 regulatory T-cell-rich and exhausted T-effector microenvironment. <i>Blood</i> , 2018 , 132, 825-836	2.2	85
68	PD-1 blockade with pembrolizumab for classical Hodgkin lymphoma after autologous stem cell transplantation. <i>Blood</i> , 2019 , 134, 22-29	2.2	78
67	Axicabtagene Ciloleucel in the Non-Trial Setting: Outcomes and Correlates of Response, Resistance, and Toxicity. <i>Journal of Clinical Oncology</i> , 2020 , 38, 3095-3106	2.2	78
66	Personal neoantigen vaccines induce persistent memory T cell responses and epitope spreading in patients with melanoma. <i>Nature Medicine</i> , 2021 , 27, 515-525	50.5	69
65	Axicabtagene Ciloleucel in the Real World: Outcomes and Predictors of Response, Resistance and Toxicity. <i>Blood</i> , 2018 , 132, 92-92	2.2	55
64	The clinical trials landscape for glioblastoma: is it adequate to develop new treatments?. <i>Neuro-Oncology</i> , 2018 , 20, 1034-1043	1	46
63	Genomic Profiling of Smoldering Multiple Myeloma Identifies Patients at a High Risk of Disease Progression. <i>Journal of Clinical Oncology</i> , 2020 , 38, 2380-2389	2.2	46
62	A phase 2 study of Rituximab-Bendamustine and Rituximab-Cytarabine for transplant-eligible patients with mantle cell lymphoma. <i>British Journal of Haematology</i> , 2016 , 173, 89-95	4.5	44
61	A Phase Ib/II Trial of the First-in-Class Anti-CXCR4 Antibody Ulocuplumab in Combination with Lenalidomide or Bortezomib Plus Dexamethasone in Relapsed Multiple Myeloma. <i>Clinical Cancer Research</i> , 2020 , 26, 344-353	12.9	39

60	A peripheral immune signature of responsiveness to PD-1 blockade in patients with classical Hodgkin lymphoma. <i>Nature Medicine</i> , 2020 , 26, 1468-1479	50.5	39
59	Genomic analyses of flow-sorted Hodgkin Reed-Sternberg cells reveal complementary mechanisms of immune evasion. <i>Blood Advances</i> , 2019 , 3, 4065-4080	7.8	38
58	Clonal hematopoiesis is associated with adverse outcomes in multiple myeloma patients undergoing transplant. <i>Nature Communications</i> , 2020 , 11, 2996	17.4	34
57	Genomic analyses of PMBL reveal new drivers and mechanisms of sensitivity to PD-1 blockade. <i>Blood</i> , 2019 , 134, 2369-2382	2.2	32
56	Extramedullary Waldenström macroglobulinemia. <i>American Journal of Hematology</i> , 2015 , 90, 100-4	7.1	31
55	HSP90 inhibition overcomes ibrutinib resistance in mantle cell lymphoma. <i>Blood</i> , 2016 , 128, 2517-2526	2.2	30
54	The immunophenotypic spectrum of primary mediastinal large B-cell lymphoma reveals prognostic biomarkers associated with outcome. <i>American Journal of Hematology</i> , 2016 , 91, E436-41	7.1	29
53	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017 , 102, 1413-1423	6.6	25
52	Chimeric Antigen Receptor T-Cell Therapy-Associated Cardiomyopathy in Patients With Refractory or Relapsed Non-Hodgkin Lymphoma. <i>Circulation</i> , 2020 , 142, 1687-1690	16.7	24
51	PD-1 blockade for diffuse large B-cell lymphoma after autologous stem cell transplantation. <i>Blood Advances</i> , 2020 , 4, 122-126	7.8	24
50	Rituximab/bendamustine and rituximab/cytarabine induction therapy for transplant-eligible mantle cell lymphoma. <i>Blood Advances</i> , 2020 , 4, 858-867	7.8	21
49	Short telomere length predicts nonrelapse mortality after stem cell transplantation for myelodysplastic syndrome. <i>Blood</i> , 2020 , 136, 3070-3081	2.2	13
48	Panobinostat in combination with rituximab in heavily pretreated diffuse large B-cell lymphoma: Results of a phase II study. <i>Hematological Oncology</i> , 2018 , 36, 633-637	1.3	12
47	Pembrolizumab in Patients with Relapsed or Refractory Primary Mediastinal Large B-Cell Lymphoma (PMBCL): Data from the Keynote-013 and Keynote-170 Studies. <i>Blood</i> , 2018 , 132, 228-228	2.2	11
46	Progression signature underlies clonal evolution and dissemination of multiple myeloma. <i>Blood</i> , 2021 , 137, 2360-2372	2.2	9
45	Targetable subsets of non-Hodgkin lymphoma in Malawi define therapeutic opportunities. <i>Blood Advances</i> , 2016 , 1, 84-92	7.8	6
44	The Role of Clonal Hematopoiesis of Indeterminate Potential (CHIP) in Multiple Myeloma: Immunomodulator Maintenance Post Autologous Stem Cell Transplant (ASCT) Predicts Better Outcome. <i>Blood</i> , 2018 , 132, 749-749	2.2	6
43	Phase 1b study of panobinostat in combination with lenalidomide, bortezomib, and dexamethasone in relapsed refractory multiple myeloma. <i>Journal of Clinical Oncology</i> , 2016 , 34, 8014-8014	2.2	6

42	Autologous stem cell transplantation after anti-PD-1 therapy for multiply relapsed or refractory Hodgkin lymphoma. <i>Blood Advances</i> , 2021 , 5, 1648-1659	7.8	6
41	Phase 1 open-label study of panobinostat, lenalidomide, bortezomib + dexamethasone in relapsed and relapsed/refractory multiple myeloma. <i>Blood Cancer Journal</i> , 2021 , 11, 20	7	6
40	Single 6-mg dose of rasburicase: The experience in a large academic medical center. <i>Journal of Oncology Pharmacy Practice</i> , 2019 , 25, 1349-1356	1.7	5
39	Rituximab/Bendamustine and Rituximab/Cytarabine (RB/RC) Induction Chemotherapy for Transplant-Eligible Patients with Mantle Cell Lymphoma: A Pooled Analysis of Two Phase 2 Clinical Trials and Off-Trial Experience. <i>Blood</i> , 2018 , 132, 145-145	2.2	4
38	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma: First Report of Efficacy and Safety. <i>Blood</i> , 2019 , 134, 1898-1898	2.2	4
37	Chromosome 9p24.1/PD-L1/PD-L2 Alterations and PD-L1 Expression and Treatment Outcomes in Patients with Classical Hodgkin Lymphoma Treated with Nivolumab (PD-1 Blockade). <i>Blood</i> , 2016 , 128, 2923-2923	2.2	4
36	The clinical and functional effects of TERT variants in myelodysplastic syndrome. <i>Blood</i> , 2021 , 138, 898-911	2.1	4
35	PD-1 Blockade for Diffuse Large B-Cell Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 706-706	2.2	3
34	Telomere Length and Telomerase Complex Mutations Predict Fatal Treatment Toxicity after Stem Cell Transplantation in Patients with Myelodysplastic Syndrome. <i>Blood</i> , 2018 , 132, 796-796	2.2	3
33	Imatinib mesylate lacks efficacy in relapsed/refractory peripheral T cell lymphoma. <i>Leukemia and Lymphoma</i> , 2015 , 56, 993-8	1.9	2
32	PD-1 Blockade with Pembrolizumab for Classical Hodgkin Lymphoma after Autologous Stem Cell Transplantation. <i>Blood</i> , 2018 , 132, 1650-1650	2.2	2
31	A Phase II Study of Brentuximab Vedotin Plus Adriamycin and Dacarbazine without Radiation in Non-Bulky Limited Stage Classical Hodgkin Lymphoma. <i>Blood</i> , 2018 , 132, 1654-1654	2.2	2
30	Interrogation of Individual CLL Loss-of-Function Lesions By CRISPR In Vivo Editing Reveals Common and Unique Pathway Alterations. <i>Blood</i> , 2019 , 134, 684-684	2.2	2
29	Genetic Alterations Predict Outcomes in Patients with Myelodysplastic Syndrome Receiving Allogeneic Hematopoietic Stem Cell Transplantation. <i>Blood</i> , 2016 , 128, 69-69	2.2	2
28	Mind the gap: Expediting gender parity in MD-PhD admissions. <i>JCI Insight</i> , 2020 , 5,	9.9	2
27	Overall survival with warfarin vs. low-molecular-weight heparin in cancer-associated thrombosis. <i>Journal of Thrombosis and Haemostasis</i> , 2021 , 19, 2825-2834	15.4	2
26	Humoral and cellular immunogenicity of SARS-CoV-2 vaccines in chronic lymphocytic leukemia: a prospective cohort study.. <i>Blood Advances</i> , 2022 ,	7.8	1
25	Dissecting Richter's Syndrome in a Multiplexed CRISPR-Based Mouse Model Reveals Key Changes in MYC, Interferon and BCR Signaling Underlying Transformation. <i>Blood</i> , 2021 , 138, 251-251	2.2	1

24	A Phase II Study of Daratumumab in Patients with High-Risk MGUS and Low-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1649-1649	2.2	1
23	PD-L1 and PD-L2 Genetic Alterations Define Classical Hodgkin Lymphoma and Predict Outcome. <i>Blood</i> , 2015 , 126, 176-176	2.2	1
22	A Phase II Trial of the Combination of Ixazomib, Lenalidomide, and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 2749-2749	2.2	0
21	Single-Cell RNA-Sequencing Identifies Immune Biomarkers of Response to Immunotherapy in Patients with High-Risk Smoldering Myeloma. <i>Blood</i> , 2021 , 138, 330-330	2.2	0
20	Clonal Hematopoiesis Prevalence Increases throughout Treatment of Newly Diagnosed Multiple Myeloma Patients. <i>Blood</i> , 2021 , 138, 1091-1091	2.2	0
19	Outcome of Autologous Stem Cell Transplantation Following PD-(L)1 Based Salvage Therapy for Multiply Relapsed Patients with Classic Hodgkin Lymphoma. <i>Blood</i> , 2019 , 134, 4571-4571	2.2	0
18	A Randomized Placebo-Controlled Phase 2 Study of Metformin for the Prevention of Progression of Monoclonal Gammopathy of Undetermined Significance and Low Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1659-1659	2.2	
17	Prognostic Value of Early PET in Patients with Aggressive Non-Hodgkin Lymphoma Treated with Anti-CD19 CAR T-Cell Therapy. <i>Blood</i> , 2021 , 138, 886-886	2.2	
16	Genomic Profiling of Smoldering Multiple Myeloma Classifies Molecular Groups with Distinct Pathogenic Phenotypes and Clinical Outcomes. <i>Blood</i> , 2021 , 138, 723-723	2.2	
15	Mapping Myeloma: A Roadmap of Daratumumab Use in Clinical Pathways. <i>Blood</i> , 2021 , 138, 4021-4021	2.2	
14	B-PRISM (Precision Intervention Smoldering Myeloma): A Phase II Trial of Combination of Daratumumab, Bortezomib, Lenalidomide and Dexamethasone in High-Risk Smoldering Multiple Myeloma. <i>Blood</i> , 2021 , 138, 4782-4782	2.2	
13	Prognostic Value of Minimal Residual Disease (MRD) Among Patients with Classical Hodgkin Lymphoma Undergoing Autologous Stem Cell Transplantation. <i>Blood</i> , 2021 , 138, 3491-3491	2.2	
12	A Phase I/II Study of Twice Weekly Ixazomib Plus Pomalidomide and Dexamethasone in Relapsed and Refractory Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1650-1650	2.2	
11	Clonal Hematopoiesis Is Frequent and Associated with Inferior Survival Irrespective of Transplantation Strategy in Patients with Newly Diagnosed Multiple Myeloma. <i>Blood</i> , 2021 , 138, 1127-1127	2.2	
10	Genetic Perturbation of CD70/CD27 Co-Stimulation Promotes the Development of Bcl6-Driven Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2021 , 138, 713-713	2.2	
9	Risks for Hospitalization and Death Among Patients with Blood Disorders from the ASH RC COVID-19 Registry for Hematology. <i>Blood</i> , 2021 , 138, 3040-3040	2.2	
8	Clinical Predictors of Outcome in Adult Patients with Acute Leukemias and Myelodysplastic Syndrome and COVID-19 Infection: Report from the American Society of Hematology Research Collaborative (ASH RC) Data Hub. <i>Blood</i> , 2021 , 138, 280-280	2.2	
7	Fetal Erythropoiesis Is Defective in Rpl11 Heterozygous Mice and Increases in Severity in Young Animals. <i>Blood</i> , 2017 , 130, 872-872	2.2	

6	The Predictive Value of PET/CT for Post-Transplant Outcomes in T Cell Lymphoma. <i>Blood</i> , 2018 , 132, 2914-2914	2.2
5	Comprehensive Analyses of Genetic Features Identify Coordinate Signatures in Diffuse Large B-Cell Lymphoma. <i>Blood</i> , 2015 , 126, 3922-3922	2.2
4	Phenotypic and Transcriptional Characterization of Non-Hodgkin Lymphomas from Malawi Defines Targetable Disease Subsets. <i>Blood</i> , 2015 , 126, 2655-2655	2.2
3	A Pilot Study of Eltrombopag Plus G-CSF for Human CD34+ Cell Mobilization in Patients with Multiple Myeloma Undergoing Autologous Stem Cell Transplant. <i>Blood</i> , 2016 , 128, 5815-5815	2.2
2	Real-world outcomes of axicabtagene ciloleucel in adult patients with primary mediastinal B-cell lymphoma. <i>Blood Advances</i> , 2021 , 5, 3563-3567	7.8
1	Survival outcomes with warfarin compared with direct oral anticoagulants in cancer-associated venous thromboembolism in the United States: A population-based cohort study. <i>PLoS Medicine</i> , 2022 , 19, e1004012	11.6